QazCovid-in

QazCovid-in
Vaccine description
Target	SARS-CoV-2
Vaccine type	Inactivated
Clinical data
Routes of administration	Intramuscular
Identifiers
CAS Number	2541708-50-1 QazCoVac-P: 2699021-46-8
DrugBank	DB16441

COVID-19 pandemic
Part of a series on the

COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths
Timeline 2019 2020 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2021 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November responses December responses 2022 January responses February responses March responses April responses May responses June responses July responses August responses September responses October responses November December 2023
Locations By country and territory Africa Antarctica Asia Europe North America Oceania South America By conveyance Cruise ships Naval ships
International response Endemic phase Evacuations Face masks International aid Origin Lockdowns by country Misinformation by governments Fake treatments Social distancing Software Travel United Nations World Health Organization WTO IP waiver Undercounting of deaths COVID-19 apps Zero-COVID National responses Africa China European Union Germany Ghana India Ireland Netherlands New Zealand Nigeria Philippines Russia Sweden UK government US federal government Vietnam
Medical response Disease testing Breathalyzer Development Drug development Drug repurposing Public health mitigation Vaccines History Research VITT Deployment Authorizations Operation Warp Speed Misinformation and hesitancy US Vaccine card Vaccine passports Current vaccines CoronaVac Covaxin Convidecia Janssen Medigen Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sinopharm BIBP Sputnik V
Variants Variants of concern Alpha Beta Gamma Delta Omicron Other variants Epsilon Zeta Eta Theta Iota Kappa Lambda Mu Cluster 5 Lineage B.1.617
Economic impact and recession Arts and culture Aviation Cannabis Cinema films Disney Fashion Financial markets Food industry Food security Journalism Music Performing arts Retail Shipping Television US sportscasting programs Tourism Video games By country Canada India Ireland Malaysia New Zealand Russia UK US By sport Association football Baseball Basketball Combat sports Cricket Disc golf Gaelic games Gridiron football Ice hockey Motorsport Rugby league
Impacts Long COVID Neurological and psychological symptoms Post-exertional malaise Society African diaspora Animals Alzheimer's disease patients Crime Death rates by country Disability Domestic violence Emergency evacuations Education Female Environment Hospitals Language LGBTQ community Long-term care Media coverage Mental health Migration Military Notable deaths Other health issues Popular culture Protests Pregnancy Prisons Religion Catholic Church Hajj Science and technology Social media Strikes Suicides Telehealth Xenophobia and racism Politics Diplomacy Ireland Malaysia New Zealand Russia UK US
COVID-19 portal

QazCovid-in, commercially known as QazVac,^[1]^[2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.^[3]^[4] QazCoVac-P was the second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.^[5]

^ Kumenov A (1 April 2021). "Kazakhstan: Officials under fire over vaccination failures". Eurasianet. Retrieved 11 April 2021.
^ Tatyana K (31 March 2021). "Vaccination with homegrown QazVac vaccine likely to start in late April". www.inform.kz. Retrieved 11 April 2021.
^ Yergaliyeva A (20 December 2020). "Kazakhstan Begins Vaccinating 3,000 Volunteers With Self-Made QazCovid-in". The Astana Times. Retrieved 2 March 2021.
^ Clinical trial number NCT04691908 for "Immunogenicity, Efficacy and Safety of QazCovid-in® COVID-19 Vaccine" at ClinicalTrials.gov
^ Arystanbek A. "Kazakh Biosafety Research Institute Begins Clinical Trials of Another Vaccine Against COVID-19". The Astana Times.